Global Women’s Health Therapeutics Market Size study & Forecast, by Type( Infection, Pregnancy, Oncology) and Regional Analysis, 2022-2029

Global Women’s Health Therapeutics Market Size study & Forecast, by Type( Infection, Pregnancy, Oncology) and Regional Analysis, 2022-2029

Global Women’s Health Therapeutics Market is valued approximately USD 151.33 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 10.0% over the forecast period 2022-2029. Medical procedures, tools, and services aimed at identifying and enhancing women's health are referred to as therapeutics for women's health. The Women’s Health Therapeutics market is expanding because of factors such as growing incidence of chronic health conditions among women, demand for contraceptives to prevent unintended pregnancies. In addition, rising healthcare spending for cancer and infectious disease early detection, pregnancy-related difficulties, and the introduction of new and potent medications are projected to further propel the market.

According to report from world health organization, in 2020, there were 2.3 million women diagnosed with breast cancer which increased from 1.68 million in year 2012. Furthermore, According to a research article by Guttmacher Institute in March 2021, it was estimated that approximately 2.4 million of adolescent women in India want to avoid pregnancy and in need of modern contraception. Thus, the rise in prevalence of cancer and demand for Contraceptives to Prevent Unintended Pregnancies is fostering the market growth. In addition, growing awareness and introduction of new drug therapies, High prevalence of infectious diseases among women is creating a lucrative growth to the market. However, the high cost of Women’s Health Therapeutics stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Women’s Health Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific dominated the market in terms of revenue, owing to the dominance of branded products, rising target population, rising investment in product development activities. Whereas North America is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Bayer AG
Merck & Co., Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
Novartis AG
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd

Recent Developments in the Market:
 In January 2021, to prevent postpartum bleeding, Sun Pharmaceutical Industries Ltd. and Ferring Pharmaceuticals Pvt. Ltd. launched the obstetric medication CARITEC in India.
 In May 2018, Pfizer initiated a Phase III trial for the ovarian cancer drug Avelumab, which can be used in conjunction with chemotherapy. This is anticipated to increase their treatment offerings and provide communities and customers with top-notch care.

Global Women’s Health Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Infection
Pregnancy
Oncology

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Bayer AG
Merck & Co., Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
Novartis AG
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.